BiomX has published promising phase 1b/2a trial results in Nature Communications, demonstrating that its phage cocktail BX004 ...

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

Biotech company VarmX has received clearance from the US FDA to begin a phase 3 trial of its lead candidate, VMX-C001, in ...

PulseSight Therapeutics has announced that the first patient has been dosed in its phase 1 clinical trial evaluating PST-611, ...

The Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for treating osteoporosis in postmenopausal women ...

Clinigen, the global pharmaceutical services Group, has appointed seasoned biopharma executive Paul Carter as Non-Executive Chair of its Board. This move strengthens the Board as Clinigen advances its ...

The first haemophilia B patient in Germany has been treated with the one-time gene therapy HEMGENIX at the Hemophilia Treatment Center at Hannover Medical School, CSL Behring Germany has announced.